Fondaparinux Market Size & Forecast Report, 2011 - 2024

Global Fondaparinux Market is expected to reach USD 686.3 billion by 2024. Fondaparinux is also termed as Fondaparinux sodium or Natural heparin pentasaccharide is an anticoagulant medication chemically related to low molecular weight heparins. Its trade name is Arixtra. Its molecular formula is C31H53N3O49S8 and molecular weight is 1508.217 g/mol. Factor Xa inhibits its activity and interrupts the blood coagulation cascade by stopping thrombus development and thrombin formation. It is a synthetic glucopyranoside with antithrombotic activity. The Fondaparinux Market is estimated to grow at a significant CAGR of 7.8% over the forecast period as the scope and its applications are rising enormously across the globe.

Growing number of hip and knee surgeries, mounting cooperation between major players for securing the intellectual property rights (IPRs), growing aging population and diseases like orthopedic conditions and heart infections are documented as major factors of Fondaparinux Market that are estimated to enhance the growth in the years to come. However, severe side effects of drugs may restrain overall market in the coming years. Fondaparinux Market is segmented based on product type, application, end user, and region.

Generics drug and branded drug are the product types that could be explored in Fondaparinux during the forecast period. The market may be categorized based on applications like abdominal surgery, orthopedics (knee or hip replacement), cardiovascular, and others that could be explored in the forecast period. Home care settings, clinics, ambulatory surgical centers, hospitals, diagnostic centers, and other end users could be explored in Fondaparinux during the forecast period.

Globally, North America accounted for the substantial market share of Fondaparinux and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be presence of key manufacturers in the region, growing awareness among populace regarding brand and upcoming drugs, and technological enhancements as growing aging population. The United States is a major consumer of Fondaparinux in this region.

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise growing awareness among patients and healthcare sectors and developing industries in this region. The developing countries like India and China are the major consumers of Fondaparinux in this region.

The key players of Fondaparinux industry are Kaifeng Pharmaceutical, Pfizer, Inc., WisMed Pharmaceuticals, Bayer Healthcare AG, Eisai Inc., GlaxoSmithKline Plc., Bristol-Myers Squibb Company, BoehringerIngelheim, Aspen Holdings, Sanofi S.A., Abbott India Limited, and Apotex. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As companies all over the world have to believe that alliance with a market would permit them proportional market existence and authority to declare the leadership position.

Market Segment:

Fondaparinux market, product outlook by revenue (USD Million, 2011 - 2024)
    • Branded
    • Generics

Fondaparinux market, product outlook by volume (thousand units, 2011 - 2024)
    • Branded
    • Generics

Fondaparinux market, regional outlook by revenue (USD Million, 2011 - 2024)
    • North America
    • Europe
    • Asia Pacific
    • China
    • RoW

Fondaparinux market, regional outlook by volume (thousand units, 2011 - 2024)
    • North America
    • Europe
    • Asia Pacific
    • China
    • RoW